Clinical trials: Randomized Controlled Trial, Human Study
- Condition Randomized Controlled Trial, Human Study
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
HCV
TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers
The purpose of this study is to evaluate the safety and tolerability of three different doses of TMC435350 compared to placebo in healthy Japanese males.
- Trial name
- NCT00752544
- Testing
- TMC435350
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1
PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
The purpose of the study is to determine the safety, tolerability and plasma pharmacokinetics (pk) (i.e., the levels of TMC558445 circulating in your blood over time) of increasing single oral doses of TMC558445 and of multiple…
- Trial name
- NCT00838760
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Hepatitis b
A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects
This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics.
- Trial name
- NCT06085053
- Testing
- TQA3038 injection
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis E
Study of AT-587 in Healthy Subjects
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects
- Trial name
- NCT07728487
- Testing
- AT-587
- Where
- Belgium
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Influenza, Human
Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
This is a phase I, double-blind, randomized, placebo-controlled trial with two groups of subjects to receive seasonal trivalent inactivated split virion influenza vaccine (A/H1N1; A/H3N2 and B strains) or placebo (phosphate…
- Trial name
- IVACFLU-S (NCT02598089)
- Testing
- Trivalent Seasonal Influenza Vaccine
- Where
- Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Healthy
Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 first in human clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous…
- Trial name
- NCT05701644
- Testing
- C1K 150mg, C1K 300mg, C1K 600mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ensol Bioscience
Autoimmune Diseases, Multiple Sclerosis
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
- Trial name
- NCT05853835
- Testing
- LPX-TI641
- Where
- 2 sites in United States, Jordan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LAPIX Therapeutics Inc.
Influenza
Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.
The goal of this study is to determine whether Fluviral, an inactivated, injectable trivalent influenza vaccine (flu shot) is effective in preventing respiratory illnesses that are severe enough to limit normal daily activities…
- Trial name
- NCT00216242
- Testing
- Influenza virus vaccine (Fluviral)
- Where
- 43 sites in United States
- Volunteers
- 7,400 people, healthy volunteers welcome
- Sponsor
- ID Biomedical Corporation, Quebec
Diphtheria, Tetanus
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults
This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT05952596
- Testing
- DTaP-HepB-IPV-Hib vaccine
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy Volunteers
SAD and MAD Study With IV and SC Doses of ARGX-117
This is a phase 1, first-in-human, double-blinded, randomized, placebo-controlled, escalating single and multiple dose levels trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ARGX-117…
- Trial name
- ARGX-117 (NCT04532125)
- Testing
- ARGX-117, ARGX-117 + rHuPH20, ARGX-117 PH20 SC
- Where
- Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- argenx
Healthy
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
- Trial name
- NCT02117934
- Testing
- HEPLISAV, Engerix-B
- Where
- 40 sites in United States
- Volunteers
- 8,374 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Common Cold
Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection
Pomegranate has a long history of use in folk medicine. There is vast data on the health benefits of pomegranate fruit and juice.
- Trial name
- NCT00655031
- Testing
- Pomegranate Concentrate (POMx)
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- POM Wonderful LLC
Hepatitis C
TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of increasing oral doses of TMC435350 after single and repeated dosing, followed by an open label repeated dosing session in 6 HCV genotype1…
- Trial name
- NCT00938899
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers
This is a first in man, prospective, single-center, randomized, double-blind, dose-escalation cohort study to investigate tolerability, safety and pharmacokinetics of rVIIa-FP in comparison to placebo.
- Trial name
- NCT01542619
- Testing
- rVIIa-FP
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Influenza, Human
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
Elderly healthy subjects will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..
- Trial name
- NCT03657719
- Testing
- GC3114, GCFLU Quadrivalent
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Healthy
Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer
The purpose of this study to evaluate the safety of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) in comparison with Fluarix Prefilled Syringe (inactivated split influenza vaccine) after…
- Trial name
- NCT02330003
- Testing
- IL-YANG FLU Vaccine Prefilled Syringe INJ., Fluarix Prefilled Syringe
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Asthma
A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma
This is a first in human clinical study. Part 1 of the clinical study will assess the safety and tolerability, as well as the single dose pharmacokinetics (PK), of inhaled AZD4604 in healthy volunteers (Part 1a, single ascending…
- Trial name
- NCT04769869
- Testing
- AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Endometriosis
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670
In this Phase I study, the primary objective is to investigate the safety and tolerability of SKI2670 after oral administration in healthy female subjects.
- Trial name
- NCT02202408
- Testing
- SKI2670
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.